BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2017-11-26
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of BIBW 2992 compared to standard first-line
chemotherapy in patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR
activating mutation